Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: The innovative force behind Ultimovacs' cancer vaccine

Zelluna

Promising clinical data reinforce the fact that Ultimovacs' universal cancer vaccine UV1 has the potential to become a new line of treatment for cancer patients. The company's broad clinical pipeline evaluating the candidate is the culmination of decades of research led by one of the pioneers in cancer immunotherapy, Professor Gustav Gaudernack. BioStock was able to get in touch with Professor Gaudernack, who is currently CSO at Ultimovacs, to learn more about his work.

Read the interview with Professor Gustav Gaudernack at biostock.se:

The innovative force behind Ultimovacs' cancer vaccine - BioStock (https://www.biostock.se/en/2022/12/den-innovativa-kraften-bakom-ultimovacs-cancervaccin/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.